Study comparing bone biopsy done with help of both MRI and CT scan with bone biopsy done using CT scan alone

Comparison between Magnetic Resonance Imaging assisted Computed Tomography-guided biopsy using fusion imaging technology (FUSEIT) and conventional Computed Tomography guided biopsy in bone lesions. A Randomized Control Trial. - NIL

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/03/105909

Enrollment

Registered

2026-03-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M00-M99- Diseases of the musculoskeletal system and connective tissue

Interventions

Intervention1: MRI Assisted CT Guided Bone Biopsy Using Fusion Imaging: CT guided bone biopsy performed with fusion of pre biopsy MRI images including STIR and diffusion weighted imaging sequences to

Eligibility

Inclusion criteria

Inclusion criteria: Patients with bone lesions amenable to CT guided biopsy as assessed by consultant radiologist. Patients with associated soft tissue mass or fluid collection where biopsy or aspiration can be performed. Patients having pre biopsy MRI with STIR and diffusion weighted imaging sequences available for fusion. Patients willing to provide written informed consent.

Exclusion criteria

Exclusion criteria: Bone lesions not amenable to CT guided biopsy in a safe manner. Patients unable to cooperate during the procedure. Non availability of pre biopsy MRI for fusion analysis. Patients with contraindications to percutaneous procedures such as uncorrected coagulopathy or pregnancy. Patients refusing consent for participation.

Design outcomes

Primary

Measure	Time frame
Diagnostic yield defined as proportion of biopsies providing conclusive histopathological diagnosis in MRI assisted CT guided biopsy compared with conventional CT guided biopsy assessed after histopathological and or microbiological examination.Timepoint: 2 weeks after the biopsy is performed.	—

Secondary

Measure	Time frame
Procedure related complications including major & minor complications.Timepoint: At baseline.;Association of imaging parameters such as lesion size, lesion type lytic or sclerotic, STIR signal intensity ratio, ADC ratio & CT attenuation with diagnostic yield.Timepoint: 2 weeks after biopsy;Diagnostic yield of concomitant soft tissue biopsy or fluid aspiration associated with bone lesions.Timepoint: 2 weeks after biopsy;Pain score measured using visual analog scale.Timepoint: At baseline	—

Measure

Time frame

Procedure related complications including major & minor complications.Timepoint: At baseline.;Association of imaging parameters such as lesion size, lesion type lytic or sclerotic, STIR signal intensity ratio, ADC ratio & CT attenuation with diagnostic yield.Timepoint: 2 weeks after biopsy;Diagnostic yield of concomitant soft tissue biopsy or fluid aspiration associated with bone lesions.Timepoint: 2 weeks after biopsy;Pain score measured using visual analog scale.Timepoint: At baseline

—

Countries

India

Contacts

Public ContactSameer Peer

AIIMS, Bathinda

sameer.peer602@gmail.com9797722727

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026